Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Vuky, Jacqueline; Vasant Balar, Arjun; Castellano, Daniel; H. O’Donnell, Peter; Grivas, Petros; Bellmunt, Joaquim; Powles, Thomas; F. Bajorin, Dean; M. Hahn, Noah; J. Savage, Mary; Fang, Xiao; Luke Godwin, James; L. Frenkl, Tara; Homet Moreno, Blanca; de Wit, Ronald; R. Plimack, Elizabeth

doi:10.1200/jco.19.01213

Public

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Published in Journal of Clinical Oncology • Jun 17, 2020

Authors:

Jacqueline Vuky

Arjun Vasant Balar

Daniel Castellano

Abstract

PURPOSE: The phase II single-arm KEYNOTE-052 study evaluated the efficacy and safety of first-line pembrolizumab for patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma (UC). PATIENTS AND METHODS: Three hundred seventy patients received pembrolizumab 200 mg intrave...

Subject

Medicine

Pembrolizumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!